BeyondSpring Files 2025 Annual Report on Form 10-K
BeyondSpring Inc., a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, announced the filing of its 2025 annual report on Form 10-K with the SEC. The report includes audited consolidated financial statements and details about its pipeline, including the late-stage clinical asset Plinabulin targeting non-small cel…